针对TRAP1-依赖的代谢重编程,以克服静止乳腺癌中多克索鲁比辛耐药性的目标

相关实验视频

Updated: May 22, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Muhammad Zubair Saleem¹, Ruyi Huang¹, Yingying Huang²

¹School of Pharmacy, Fujian Medical University, Fuzhou 350122, China; Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, Fujian Medical University, Fuzhou 350122, China.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

|March 14, 2025

概括

一种新型的抑制剂,C210,准TRAP1以消除耐药的静止乳腺癌细胞. 这种方法破坏了细胞生物能量,特别是针对氧化酸化 (OXPHOS) 消除癌细胞.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生化学

背景情况:

热冲击蛋白90 (HSP90) 和它的同类TRAP1都与癌细胞代谢和耐药性有关.
静止的乳腺癌细胞表现出代谢重编程和对常规化疗,如多克索鲁比 (DOX) 的耐药性.

研究的目的:

研究一种新型HSP90抑制剂C210在静止乳腺癌细胞中克服DOX抵抗的疗效.
阐明C210针对TRAP1并影响细胞代谢和生存的机制.

主要方法:

通过缺氧和葡萄糖剥夺诱导乳腺癌细胞静止.
使用西式抹杀,ECAR,OCR,线粒体复合体活动测定和蛋白质组分析评估细胞代谢.
使用SPR和免疫沉来研究C210的点和功能,在小鼠瘤模型中评估体内疗效.

主要成果:

在缺氧和低葡萄糖下静止细胞显示TRAP1升高,氧化酸化增强 (OXPHOS) 和DOX抗性,但对C210.0敏感.
C210破坏了TRAP1的相互作用,导致OXPHOS蛋白质的蛋白质酶体降解,减少线粒体呼吸,以及静止细胞中的亡.
此外,C210还准了甘氨酸,氨基酸和β-氧化通路,在体内显示出与OXPHOS抑制相关的显著抗癌活性.

结论:

C210有效地消除了耐多克索鲁比的静止乳腺癌细胞.
该机制涉及针对TRAP1依赖的生物能量和抑制OXPHOS.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.药物耐药性药物耐药性药物耐药性在HSP90中,它是HSP90的.氧化酸化是一种氧化酸化.静止是一种静止.在TRAP1中,TRAP1是TRAP1.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...